EMVC - Ticker AI Digest

EMV Capital plc 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (EMVC) 1
EMVC 06:01
EMV Capital plc
Interim Results and Investor Presentation
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow"></mark>
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 1
EMVC 06:01
EMV Capital plc
Asset Purchase Agreement with Destiny Pharma
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
EMV Capital plc, a deep tech and life sciences venture capital investment group, announced that its subsidiary, Moirai Acquisitions Limited (Bidco), has entered into an asset purchase agreement (APA) with Destiny Pharma Limited, a company in liquidation. The agreement involves the acquisition of certain assets related to Destiny Pharmas XF drug platform, specifically the compound XF-73, for a total consideration of up to £2,475,000. The XF platform is a novel, ultra-rapid mechanism designed to reduce bacterial resistance and offers advantages over traditional antibiotics.
**Key Terms of the APA**
**Initial Consideration** £475,000 (plus VAT) funded by a third-party syndicated loan with warrant coverage.
**Deferred Consideration** Up to £2 million (plus VAT), contingent on future milestones
£600,000 upon launching a Phase 3 clinical trial in the U.S.
£900,000 upon receiving U.S. regulatory approval for XF-73.
Up to £500,000 from a milestone fee tied to net sales under a regional development agreement.
**Funding and Structure**
Bidco plans further fundraising to cover Phase 3 trial costs, regulatory approval, and deferred consideration.
EMV Capital Partners led an equity fundraising round of up to £725,000 for Bidcos working capital, expected to complete in September 2025.
Post-acquisition, Bidcos value (c.£1.86 million) will be added to EMV Capitals assets under management, with EMV Capital retaining a 30% stake on a fully diluted basis.
**About XF-73 and Destiny Pharma**
XF-73 targets post-surgical site infections, addressing the global issue of antibiotic-resistant bacteria like MRSA.
Destiny Pharma, previously AIM-quoted, entered administration in August 2024 and liquidation in August 2025, after completing a Phase 2b trial for its nasal gel.
**Strategic Importance**
EMV Capital emphasizes the investments social impact, addressing antimicrobial resistance, a major global health threat.
Dr. Ilian Iliev, CEO of EMV Capital, highlighted the capital-efficient approach and the potential of XF-73 in preventing hospital infections.
**Conclusion**
The acquisition strengthens EMV Capitals portfolio in the life sciences sector, leveraging its venture-building expertise to advance XF-73 while addressing critical public health challenges.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 2
EMVC 06:01
EMV Capital plc
Interim Results and Investor Presentation
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow"></mark>
EMVC 06:01
EMV Capital plc
Notice of Interim Results
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 3
EMVC 06:01
EMV Capital plc
Interim Results and Investor Presentation
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow"></mark>
EMVC 06:01
EMV Capital plc
Asset Purchase Agreement with Destiny Pharma
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
EMV Capital plc, a deep tech and life sciences venture capital investment group, announced that its subsidiary, Moirai Acquisitions Limited (Bidco), has entered into an asset purchase agreement (APA) with Destiny Pharma Limited, a company in liquidation. The agreement involves the acquisition of certain assets related to Destiny Pharmas XF drug platform, specifically the compound XF-73, for a total consideration of up to £2,475,000. The XF platform is a novel, ultra-rapid mechanism designed to reduce bacterial resistance and offers advantages over traditional antibiotics.
**Key Terms of the APA**
**Initial Consideration** £475,000 (plus VAT) funded by a third-party syndicated loan with warrant coverage.
**Deferred Consideration** Up to £2 million (plus VAT), contingent on future milestones
£600,000 upon launching a Phase 3 clinical trial in the U.S.
£900,000 upon receiving U.S. regulatory approval for XF-73.
Up to £500,000 from a milestone fee tied to net sales under a regional development agreement.
**Funding and Structure**
Bidco plans further fundraising to cover Phase 3 trial costs, regulatory approval, and deferred consideration.
EMV Capital Partners led an equity fundraising round of up to £725,000 for Bidcos working capital, expected to complete in September 2025.
Post-acquisition, Bidcos value (c.£1.86 million) will be added to EMV Capitals assets under management, with EMV Capital retaining a 30% stake on a fully diluted basis.
**About XF-73 and Destiny Pharma**
XF-73 targets post-surgical site infections, addressing the global issue of antibiotic-resistant bacteria like MRSA.
Destiny Pharma, previously AIM-quoted, entered administration in August 2024 and liquidation in August 2025, after completing a Phase 2b trial for its nasal gel.
**Strategic Importance**
EMV Capital emphasizes the investments social impact, addressing antimicrobial resistance, a major global health threat.
Dr. Ilian Iliev, CEO of EMV Capital, highlighted the capital-efficient approach and the potential of XF-73 in preventing hospital infections.
**Conclusion**
The acquisition strengthens EMV Capitals portfolio in the life sciences sector, leveraging its venture-building expertise to advance XF-73 while addressing critical public health challenges.
EMVC 06:01
EMV Capital plc
Notice of Interim Results

AI Crunch

Single-Ticker AI Crunch
EMVC signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for EMV Capital plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full EMVC AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for EMVC on 2025-09-30.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
16221169
Enterprise Value
-
Public Float
54.82
Broker Target
136
Shares Out
27967532
Long Interest
-
Short Interest
-
Exchange
-
Currency Code
-
ISIN
None
Market
None
Sector
Unknown
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-04-01
Net Debt
586000.0
Cash
949000.0
EPS
-0.1
Net Income
-3058000.0
Revenue
2450000.0
Enterprise Value
-
Trailing PE
-
Forward PE
-
Price Sales TTM
6.8763
Price Book MRQ
1.0943
EV Revenue
7.2739
EV EBITDA
-5.0645

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
34.7149
Institutions As Of
2025-12-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
5
Sale Director Dealing
0
Purchase TR1
2
Sale TR1
2
Broker Coverage Rows
0
Institution Holders Tracked
3
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit EMVC.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-09-30 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
EMV Capital plc has fresh news flow feeding the chart narrative.
AI Charts Studio
EMVC Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-09-30 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 10.44%
RSI Gauge
Price Change
AI Forecast